Bayer announced today initiation of a Phase I clinical trial with 225 Ac-GPC3 (BAY 3547926), an investigational targeted alpha radiopharmaceutical being developed to treat tumors expressing Glypican-3 ...

GPC3-CAR T cells armed with IL-15 were evaluated in the second patient cohorts that again included adults (NCT05103631) and ...

The clinical trial will include nearly 150 patients with advanced hepatocellular carcinoma that expresses glypican-3.

In a statement, Ipsen said that GPC3 is a well-validated target in oncology and is highly expressed across several tumour types, including hepatocellular carcinoma (HCC). Meanwhile, MAIT cells are ...

Bayer begins phase I study targeting GPC3 with actinium-225 radiopharmaceutical in patients with advanced hepatocellular carcinoma: Berlin Wednesday, April 30, 2025, 12:00 Hrs [IS ...

Berlin: Bayer has announced the initiation of a Phase I clinical trial with 225Ac-GPC3 (BAY 3547926), an investigational ...

225 Ac-GPC3 (BAY 3547926) is an investigational targeted alpha radiopharmaceutical being developed to treat tumors expressing Glypican-3 (GPC3) in patients with advanced hepatocellular carcinoma ...

WHIPPANY, N.J.--(BUSINESS WIRE)--Bayer announced today initiation of a Phase I clinical trial with 225 Ac-GPC3 (BAY 3547926), an investigational targeted alpha radiopharmaceutical being developed ...